PMID- 37365840 OWN - NLM STAT- MEDLINE DCOM- 20230721 LR - 20230726 IS - 1551-4005 (Electronic) IS - 1538-4101 (Print) IS - 1551-4005 (Linking) VI - 22 IP - 13 DP - 2023 Jul TI - Mas receptor: a potential strategy in the management of ischemic cardiovascular diseases. PG - 1654-1674 LID - 10.1080/15384101.2023.2228089 [doi] AB - MasR is a critical element in the RAS accessory pathway that protects the heart against myocardial infarction, ischemia-reperfusion injury, and pathological remodeling by counteracting the effects of AT1R. This receptor is mainly stimulated by Ang 1-7, which is a bioactive metabolite of the angiotensin produced by ACE2. MasR activation attenuates ischemia-related myocardial damage by facilitating vasorelaxation, improving cell metabolism, reducing inflammation and oxidative stress, inhibiting thrombosis, and stabilizing atherosclerotic plaque. It also prevents pathological cardiac remodeling by suppressing hypertrophy- and fibrosis-inducing signals. In addition, the potential of MasR in lowering blood pressure, improving blood glucose and lipid profiles, and weight loss has made it effective in modulating risk factors for coronary artery disease including hypertension, diabetes, dyslipidemia, and obesity. Considering these properties, the administration of MasR agonists offers a promising approach to the prevention and treatment of ischemic heart disease.Abbreviations: Acetylcholine (Ach); AMP-activated protein kinase (AMPK); Angiotensin (Ang); Angiotensin receptor (ATR); Angiotensin receptor blocker (ARB); Angiotensin-converting enzyme (ACE); Angiotensin-converting enzyme inhibitor (ACEI); Anti-PRD1-BF1-RIZ1 homologous domain containing 16 (PRDM16); bradykinin (BK); Calcineurin (CaN); cAMP-response element binding protein (CREB); Catalase (CAT); C-C Motif Chemokine Ligand 2 (CCL2); Chloride channel 3 (CIC3); c-Jun N-terminal kinases (JNK); Cluster of differentiation 36 (CD36); Cocaine- and amphetamine-regulated transcript (CART); Connective tissue growth factor (CTGF); Coronary artery disease (CAD); Creatine phosphokinase (CPK); C-X-C motif chemokine ligand 10 (CXCL10); Cystic fibrosis transmembrane conductance regulator (CFTR); Endothelial nitric oxide synthase (eNOS); Extracellular signal-regulated kinase 1/2 (ERK 1/2); Fatty acid transport protein (FATP); Fibroblast growth factor 21 (FGF21); Forkhead box protein O1 (FoxO1); Glucokinase (Gk); Glucose transporter (GLUT); Glycogen synthase kinase 3beta (GSK3beta); High density lipoprotein (HDL); High sensitive C-reactive protein (hs-CRP); Inositol trisphosphate (IP3); Interleukin (IL); Ischemic heart disease (IHD); Janus kinase (JAK); Kruppel-like factor 4 (KLF4); Lactate dehydrogenase (LDH); Left ventricular end-diastolic pressure (LVEDP); Left ventricular end-systolic pressure (LVESP); Lipoprotein lipase (LPL); L-NG-Nitro arginine methyl ester (L-NAME); Low density lipoprotein (LDL); Mammalian target of rapamycin (mTOR); Mas-related G protein-coupled receptors (Mrgpr); Matrix metalloproteinase (MMP); MAPK phosphatase-1 (MKP-1); Mitogen-activated protein kinase (MAPK); Monocyte chemoattractant protein-1 (MCP-1); NADPH oxidase (NOX); Neuropeptide FF (NPFF); Neutral endopeptidase (NEP); Nitric oxide (NO); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB); Nuclear-factor of activated T-cells (NFAT); Pancreatic and duodenal homeobox 1 (Pdx1); Peroxisome proliferator- activated receptor gamma (PPARgamma); Phosphoinositide 3-kinases (PI3k); Phospholipase C (PLC); Prepro-orexin (PPO); Prolyl-endopeptidase (PEP); Prostacyclin (PGI2); Protein kinase B (Akt); Reactive oxygen species (ROS); Renin-angiotensin system (RAS); Rho-associated protein kinase (ROCK); Serum amyloid A (SAA); Signal transducer and activator of transcription (STAT); Sirtuin 1 (Sirt1); Slit guidance ligand 3 (Slit3); Smooth muscle 22alpha (SM22alpha); Sterol regulatory element-binding protein 1 (SREBP-1c); Stromal-derived factor-1a (SDF); Superoxide dismutase (SOD); Thiobarbituric acid reactive substances (TBARS); Tissue factor (TF); Toll-like receptor 4 (TLR4); Transforming growth factor beta1 (TGF-beta1); Tumor necrosis factor alpha (TNF-alpha); Uncoupling protein 1 (UCP1); Ventrolateral medulla (VLM). FAU - Molaei, Ali AU - Molaei A AD - Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Molaei, Emad AU - Molaei E AD - PharmD, Assistant of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. FAU - Hayes, A Wallace AU - Hayes AW AD - University of South Florida College of Public Health, Tampa, Florida, USA. FAU - Karimi, Gholamreza AU - Karimi G AD - Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Pharmacodynamics and Toxicology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. LA - eng PT - Journal Article PT - Review DEP - 20230626 PL - United States TA - Cell Cycle JT - Cell cycle (Georgetown, Tex.) JID - 101137841 RN - 0 (Ligands) RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Angiotensins) RN - 0 (Chemokines) SB - IM MH - Humans MH - *Cardiovascular Diseases MH - Ligands MH - *Coronary Artery Disease MH - Angiotensin Receptor Antagonists MH - Angiotensin-Converting Enzyme Inhibitors MH - Ischemia MH - Angiotensins MH - Chemokines PMC - PMC10361149 OTO - NOTNLM OT - Ang 1-7 OT - Atherosclerosis OT - Diabetes OT - Ischemic heart disease OT - MasR OT - Obesity COIS- No potential conflict of interest was reported by the authors. EDAT- 2023/06/27 06:42 MHDA- 2023/07/21 06:44 PMCR- 2024/06/26 CRDT- 2023/06/27 02:16 PHST- 2024/06/26 00:00 [pmc-release] PHST- 2023/07/21 06:44 [medline] PHST- 2023/06/27 06:42 [pubmed] PHST- 2023/06/27 02:16 [entrez] AID - 2228089 [pii] AID - 10.1080/15384101.2023.2228089 [doi] PST - ppublish SO - Cell Cycle. 2023 Jul;22(13):1654-1674. doi: 10.1080/15384101.2023.2228089. Epub 2023 Jun 26.